Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: Issues and opportunities

Joshua Beckman, Annaswamy Raji, Jorge Plutzky

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Atherosclerosis remains a major complication of type 2 diabetes mellitus. Increasing data suggest insulin resistance, and its associated metabolic abnormalities, may underlie many of the cardiovascular complications seen among patients with insulin resistance and/or diabetes mellitus. This insight has also suggested that therapeutic approaches targeting insulin resistance may not only improve metabolism but also limit complications like atherosclerosis and the inflammation that contributes to it. Thiazolidinediones, agonists of the nuclear receptor peroxisome proliferator activated receptor gamma, are one such insulin-sensitizing therapeutic intervention in current use among patients with type 2 diabetes mellitus. The existing data regarding thiazolidinedione effects on the cardiovascular system are reviewed and considered, along with the future prospects for this emerging drug class.

Original languageEnglish (US)
Pages (from-to)479-485
Number of pages7
JournalCurrent Opinion in Cardiology
Volume18
Issue number6
DOIs
StatePublished - Nov 2003
Externally publishedYes

Keywords

  • Atherosclerosis
  • Insulin resistance
  • PPAR
  • Thiazolidinedione

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: Issues and opportunities'. Together they form a unique fingerprint.

Cite this